Navigation Links
Intellikine Completes $51 Million Financing
Date:7/8/2009

LA JOLLA, Calif., July 8 /PRNewswire/ -- Intellikine, Inc., a leader in the development of innovative, small molecule drugs for the treatment of cancer, inflammation and autoimmune diseases, announced today that it has raised $51 million in preferred stock financing. Novartis Bioventures Ltd. led the financing in which additional new investors U.S. Venture Partners, Biogen Idec and FinTech Global Capital participated. Markus Goebel, M.D., Ph.D., Managing Director of the Novartis Venture Funds, will join the company's board of directors.

The investment includes a $28.5 million first closing. In addition, the company can access up to another $22.5 million, subject to the performance of certain milestones, which, if triggered, will bring the total amount raised in this round to $51 million. This latest financing comes less than two years after the company was formed with an initial investment of $12.5 million from founding investors Abingworth, CMEA Capital and Sofinnova Ventures, all of whom participated in this latest financing.

Intellikine is developing a portfolio of isoform-selective inhibitors of the phosphatidyinositol-3-kinase (PI3K) pathway for the treatment of cancer, inflammation and autoimmune diseases. The company has discovered multiple classes of proprietary compounds that are potent, selective and druglike inhibitors of PI3K isoforms. The company's most advanced compound, INK128, a selective TORC1/2 inhibitor, has demonstrated efficacy in multiple models of cancer and is expected to enter Phase I clinical studies within twelve months.

"We are delighted to have generated such excitement among both new and existing investors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Intellikine. "This financing gives us the resources necessary to advance our pipeline of PI3K/mTOR inhibitors into clinical development as well as significant flexibility to build strategic partner
'/>"/>

SOURCE Intellikine, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
2. Verenium Completes Amendment to 8% Senior Convertible Notes
3. Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
4. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
5. Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait
6. EFT BioTech Holdings, Inc.s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait
7. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
8. Cordex Completes Production of ATPace(TM) Clinical Trial Material
9. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
10. Brooks Instrument Completes Acquisition of Celerity's Instrumentation Division
11. Sinovac Completes Construction of H1N1 Virus Seed Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 Texas ... John Sharp, Texas A&M Health Science Center CEO ... Department of Health and Human Services (HHS), State ... a national pandemic influenza vaccine manufacturing facility in ... an anchor for the Texas A&M Biocorridor – ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... are undifferentiated biological cells that can differentiate into specialized ... stem cells. Stem cell therapy can be applied to ... system disease), nervous system diseases, damage or lesion of ...
(Date:9/18/2014)... Research and Markets has announced ... Report 2014" report to their offering. ... a professional and in-depth study on the current state ... report provides a basic overview of the industry including ... albumin market analysis is provided for the international markets ...
(Date:9/18/2014)... 18, 2014 Leatherwood Plastics has ... material, to stay competitive in the semiconductor, clean ... materials ultimately impact product quality and productivity, according ... , Established in 1980 in Lewisville, TX, ... fabricators have left the business. Much of Leatherwood’s ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... , BALTIMORE, Sept. 10 ... company whose personalized oncology services division assists physicians by providing ... a collaboration agreement with PinnacleCare , the ... world. , , PinnacleCare will offer Champions, ...
... , SAN DIEGO, Sept. 10 ... 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of ... that nebulized Aeroquin met the primary endpoint of reducing bacterial ... in sputum after 28 days of dosing versus placebo. ...
... , NEW HAVEN, Conn., Sept. ... a development-stage company focused on the discovery, development and ... care antibiotic-resistant infections, today announced that seven posters have ... on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in ...
Cached Biology Technology:Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 3Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 4Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients 2Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients 3Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients 4Rib-X Pharmaceuticals to Present at the 49th ICAAC 2Rib-X Pharmaceuticals to Present at the 49th ICAAC 3Rib-X Pharmaceuticals to Present at the 49th ICAAC 4
(Date:9/18/2014)... Clownfish spend their entire lives nestling in the protective ... as babies they sometimes travel hundreds of kilometres across ... by reef fish has been predicted, this is the ... between distant populations has been observed. , Dr Steve ... at the University of Exeter, and colleagues from the ...
(Date:9/17/2014)... Europaea started in 2000 as an EC-FP5 four-year project, ... of steady progress and successful participations in several EC ... Biodiversity Observation Network project (EU BON), to increase ... contributors and to extend the general dissemination of the ... has applied its novel e-Publishing tools to ...
(Date:9/17/2014)... (Hospital del Mar Medical Research Institute) and at the ... study in eLife showing that RNA called ... of new proteins, some of which could have important ... from the instructions found in an RNA molecule. However, ... information for the synthesis of proteins, meaning it is ...
Breaking Biology News(10 mins):Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Parts of genome without a known function may play a key role in the birth of new proteins 2
... evidence that Parkinson,s disease may have an infectious or ... is associated with late-onset sporadic Parkinson,s disease" appears online ... conducted by the NeuroGenetics Research Consortium, an international team ... the New York State Department of Health Wadsworth Center. ...
... State University have developed a method for predicting the ... the human body. Their work could have implications for ... of nanomaterials, as well as applications for drug delivery. ... Distinguished Professor of Pharmacology and director of the ...
... SALT LAKE CITY, July 26 Wall Street Communications ... Media, a world leader in content identification solutions, to ... a presence for the company in broadcast, government, and ... Media, based in Darmstadt, Germany, is a spinoff of ...
Cached Biology News:Researchers discover genetic link between immune system, Parkinson's disease 2Probing the nanoparticle: Predicting how nanoparticles will react in the human body 2Wall Street Communications Retained by iPharro Media 2
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic gel acid stain has also found ... bandshift assays. One mL stains 100 minigels. A ...
Synonym: modified Grace's Insect medium...
... acid synthetic peptide whose sequence is derived from bovine rhodopsin ... carboxy terminus): C - S(338) - K - T ... - A - P - A(348). This peptide ... polyclonal antibody that reacts with this product and bovine rhodopsin, ...
... The proteomic service includes protein ... analysis using the PDQuest software package ... MALDI-TOF mass spectrometry. In order to ... sample preparation, data analysis and format ...
Biology Products: